Drug developers integrate AI capabilities as a potentially transformative strategy to combat patent cliff losses.
Novo and Hims & Hers have continually locked horns over the legality of obesity drug offerings.
Lilly joins the growing list of big pharma companies hoping to see success from their acquired in vivo CAR-T programmes.
The partnership aims to advance high-priority small molecule programmes using Iambic’s AI models and wet lab capabilities.
REGENXBIO plans to request a Type A meeting with the FDA to discuss the CRL and its planned BLA resubmission.
Despite the FDA’s CNPV scheme generating high interest, the process around how voucher awards are prioritised remains unclear.
